IN2014KN02423A - - Google Patents

Info

Publication number
IN2014KN02423A
IN2014KN02423A IN2423KON2014A IN2014KN02423A IN 2014KN02423 A IN2014KN02423 A IN 2014KN02423A IN 2423KON2014 A IN2423KON2014 A IN 2423KON2014A IN 2014KN02423 A IN2014KN02423 A IN 2014KN02423A
Authority
IN
India
Prior art keywords
present
compounds
abc
cftr
transporters
Prior art date
Application number
Other languages
English (en)
Inventor
Sara S Hadida Ruah
Peter D J Grootenhuis
Frederick Van Goor
Jinglan Zhou
Brian Bear
Mark T Miller
Jason Mccartney
Mehdi Michel Jamel Numa
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of IN2014KN02423A publication Critical patent/IN2014KN02423A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00Ā -Ā C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00Ā -Ā C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
IN2423KON2014 2006-04-07 2007-04-09 IN2014KN02423A (US20080318984A1-20081225-C00010.png)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79045906P 2006-04-07 2006-04-07
PCT/US2007/008975 WO2007117715A2 (en) 2006-04-07 2007-04-09 Modulators of atp-binding cassette transporters

Publications (1)

Publication Number Publication Date
IN2014KN02423A true IN2014KN02423A (US20080318984A1-20081225-C00010.png) 2015-05-01

Family

ID=38477342

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2423KON2014 IN2014KN02423A (US20080318984A1-20081225-C00010.png) 2006-04-07 2007-04-09

Country Status (22)

Country Link
US (9) US7776905B2 (US20080318984A1-20081225-C00010.png)
EP (5) EP3091011B1 (US20080318984A1-20081225-C00010.png)
JP (3) JP5420395B2 (US20080318984A1-20081225-C00010.png)
CN (2) CN101460489A (US20080318984A1-20081225-C00010.png)
AU (1) AU2007235260B2 (US20080318984A1-20081225-C00010.png)
BR (1) BRPI0710965B8 (US20080318984A1-20081225-C00010.png)
CA (2) CA2869945C (US20080318984A1-20081225-C00010.png)
CY (3) CY1116979T1 (US20080318984A1-20081225-C00010.png)
DK (3) DK2674428T3 (US20080318984A1-20081225-C00010.png)
ES (4) ES2659364T3 (US20080318984A1-20081225-C00010.png)
HU (4) HUE055205T2 (US20080318984A1-20081225-C00010.png)
IL (1) IL194576A (US20080318984A1-20081225-C00010.png)
IN (1) IN2014KN02423A (US20080318984A1-20081225-C00010.png)
LT (1) LT3091011T (US20080318984A1-20081225-C00010.png)
MX (1) MX2008012945A (US20080318984A1-20081225-C00010.png)
NZ (3) NZ611485A (US20080318984A1-20081225-C00010.png)
PL (4) PL3091011T3 (US20080318984A1-20081225-C00010.png)
PT (3) PT2007756E (US20080318984A1-20081225-C00010.png)
RU (1) RU2451018C2 (US20080318984A1-20081225-C00010.png)
SI (4) SI3327016T1 (US20080318984A1-20081225-C00010.png)
WO (1) WO2007117715A2 (US20080318984A1-20081225-C00010.png)
ZA (1) ZA200809290B (US20080318984A1-20081225-C00010.png)

Families Citing this family (106)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
MXPA06002567A (es) 2003-09-06 2006-09-04 Vertex Pharma Moduladores de transportadores con casete de union de atp.
ES2328824T3 (es) * 2003-11-14 2009-11-18 Vertex Pharmaceuticals Incorporated Tiazoles y oxazoles utiles como moduladores de transportadores de tipo casete de union a atp.
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2005075435A1 (en) * 2004-01-30 2005-08-18 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
ES2656017T3 (es) 2004-06-24 2018-02-22 Vertex Pharmaceuticals Incorporated Moduladores de transportadores del casete de uniĆ³n a ATP
KR20080053297A (ko) 2005-08-11 2008-06-12 ė²„ķ…ģŠ¤ ķŒŒė§ˆģŠˆķ‹°ģ¹¼ģŠ¤ ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ė‚­ķ¬ģ„± ģ„¬ģœ ģ¢… ķŠøėžœģŠ¤ė§‰ ģ „ė„ė„ ģ”°ģ •ģžģ˜ ģ”°ģ ˆģž
EP1945632B1 (en) 2005-11-08 2013-09-18 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensƦtninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
EP2016065B1 (en) * 2005-12-28 2012-09-19 Vertex Pharmaceuticals Incorporated 1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropane-carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
CA2869945C (en) * 2006-04-07 2018-01-23 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US8563573B2 (en) * 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
ES2646175T3 (es) 2006-11-03 2017-12-12 Vertex Pharmaceuticals Incorporated Derivados de azaindol como moduladores de CFTR
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
JP2010523579A (ja) * 2007-04-02 2010-07-15 ć‚¤ćƒ³ć‚¹ćƒ†ć‚£ćƒ†ćƒ„ćƒ¼ćƒˆ ćƒ•ć‚©ć‚¢ ćƒÆćƒ³ćƒÆćƒ¼ćƒ«ćƒ‰ ćƒ˜ćƒ«ć‚¹ ļ¼£ļ½†ļ½”ļ½’阻害剤化合ē‰©ćŠć‚ˆć³ćć‚Œć‚‰ć®ä½æē”Ø
EP2789606B1 (en) 2007-05-09 2017-11-15 Vertex Pharmaceuticals Incorporated Modulators of CFTR
CA2687764A1 (en) * 2007-05-25 2008-12-04 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
CA2696298C (en) 2007-08-24 2016-09-06 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP3012250B1 (en) 2007-11-16 2017-11-08 Vertex Pharmaceuticals Incorporated Isoquinoline modulators of atp-binding cassette transporters
JP2011506331A (ja) * 2007-12-07 2011-03-03 ćƒćƒ¼ćƒ†ćƒƒć‚Æć‚¹ ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ļ¼“āˆ’ļ¼ˆļ¼–āˆ’ļ¼ˆļ¼‘āˆ’ļ¼ˆļ¼’ļ¼Œļ¼’āˆ’ć‚øćƒ•ćƒ«ć‚Ŗćƒ­ćƒ™ćƒ³ć‚¾ļ¼»ļ½„ļ¼½ļ¼»ļ¼‘ļ¼Œļ¼“ļ¼½ć‚øć‚Ŗć‚­ć‚½ćƒ¼ćƒ«āˆ’ļ¼•āˆ’ć‚¤ćƒ«ļ¼‰ć‚·ć‚Æćƒ­ćƒ—ćƒ­ćƒ‘ćƒ³ć‚«ćƒ«ćƒœć‚­ć‚µćƒŸćƒ‰ļ¼‰āˆ’ļ¼“āˆ’ćƒ”ćƒćƒ«ćƒ”ćƒŖć‚øćƒ³āˆ’ļ¼’āˆ’ć‚¤ćƒ«ļ¼‰å®‰ęÆ香é…øć®å‡¦ę–¹ē‰©
EP3683218B1 (en) 2007-12-07 2024-09-18 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
US20100036130A1 (en) 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
NZ612635A (en) 2007-12-07 2015-06-26 Vertex Pharma Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
EP2078711A1 (en) * 2007-12-28 2009-07-15 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor
CA2931134C (en) 2008-02-28 2019-07-30 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
SI2615085T1 (sl) 2008-03-31 2015-11-30 Vertex Pharmaceuticals Incorporated Piridilni derivati kot cftr-modulatorji
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
WO2009131958A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazine derivatives
WO2009131957A2 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
EP2341776A4 (en) * 2008-09-19 2012-05-30 Inst Oneworld Health COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING IMIDAZOL AND TRIAZOL DERIVATIVES
JP2012504143A (ja) * 2008-09-29 2012-02-16 ćƒćƒ¼ćƒ†ćƒƒć‚Æć‚¹ ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ļ¼“āˆ’ļ¼ˆļ¼–āˆ’ļ¼ˆļ¼‘āˆ’ļ¼ˆļ¼’ļ¼Œļ¼’āˆ’ć‚øćƒ•ćƒ«ć‚Ŗćƒ­ćƒ™ćƒ³ć‚¾ļ¼»ļ½„ļ¼½ļ¼»ļ¼‘ļ¼Œļ¼“ļ¼½ć‚øć‚Ŗć‚­ć‚½ćƒ¼ćƒ«āˆ’ļ¼•āˆ’ć‚¤ćƒ«ļ¼‰ć‚·ć‚Æćƒ­ćƒ—ćƒ­ćƒ‘ćƒ³ć‚«ćƒ«ćƒœć‚­ć‚µćƒŸćƒ‰ļ¼‰āˆ’ļ¼“āˆ’ćƒ”ćƒćƒ«ćƒ”ćƒŖć‚øćƒ³āˆ’ļ¼’āˆ’ć‚¤ćƒ«ļ¼‰å®‰ęÆ香é…ø恮ē”Ø量単位
BRPI0919930A2 (pt) * 2008-10-23 2016-02-16 Vertex Pharma moduladores de regulador de condutĆ¢ncia transmembrana de fibrose cĆ­stica
NZ592694A (en) * 2008-11-06 2013-05-31 Vertex Pharma ATP-Binding Cassette (ABC) transporters as modulators of CFTR activity
UA104876C2 (uk) * 2008-11-06 2014-03-25 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚Ń–ŠŗŠ°Š»Š· Š†Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ ŠœŠ¾Š“уŠ»ŃŃ‚Š¾Ń€Šø atф-Š·Š²'яŠ·ŃƒŠ²Š°Š»ŃŒŠ½Šøх ŠŗŠ°ŃŠµŃ‚Š½Šøх трŠ°Š½ŃŠæŠ¾Ń€Ń‚ŠµŃ€Ń–Š²
EP3330255B1 (en) 2009-03-20 2020-12-09 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
US8497271B2 (en) 2009-10-07 2013-07-30 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
US8426414B2 (en) 2009-10-09 2013-04-23 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
US8304577B2 (en) 2009-10-09 2012-11-06 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
CA2777245A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
HUE062892T2 (hu) * 2010-03-25 2023-12-28 Vertex Pharma (R)-1(2,2-difluorbenzo[d][1,3]dioxol-5-il)-N-(1-(2,3-dihidroxipropil)-6-fluor-2-(1-hidroxi- 2-metilpropƔn-2-il)-1H-indol-5-il)ciklopropƔnkarboxamid elƵƔllƭtƔsa Ʃs kƶztitermƩkei
HRP20211752T1 (hr) 2010-04-07 2022-02-18 Vertex Pharmaceuticals Incorporated Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
MX2012011655A (es) 2010-04-07 2012-11-23 Vertex Pharma Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo [d][1-3]dioxol-5-il]ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico.
ES2858351T3 (es) * 2010-04-22 2021-09-30 Vertex Pharma Compuesto intermedio para proceso de producciĆ³n de compuestos de cicloalquilcaraboxamido-indol
AU2011242452A1 (en) * 2010-04-22 2012-11-08 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
WO2011133956A1 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
NZ603043A (en) * 2010-04-22 2015-02-27 Vertex Pharma Pharmaceutical compositions comprising cftr modulators and administrations thereof
NZ603386A (en) 2010-05-20 2015-02-27 Vertex Pharma Pharmaceutical compositions and administrations thereof
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
JP2013536231A (ja) * 2010-08-23 2013-09-19 ćƒćƒ¼ćƒ†ćƒƒć‚Æć‚¹ ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ļ¼ˆļ½’ļ¼‰āˆ’ļ¼‘āˆ’ļ¼ˆļ¼’ļ¼Œļ¼’āˆ’ć‚øćƒ•ćƒ«ć‚Ŗćƒ­ćƒ™ćƒ³ć‚¾ļ¼»ļ½„ļ¼½ļ¼»ļ¼‘ļ¼Œļ¼“ļ¼½ć‚øć‚Ŗć‚­ć‚½ćƒ¼ćƒ«āˆ’ļ¼•āˆ’ć‚¤ćƒ«ļ¼‰āˆ’ļ½Žāˆ’ļ¼ˆļ¼‘āˆ’ļ¼ˆļ¼’ļ¼Œļ¼“āˆ’ć‚øćƒ’ćƒ‰ćƒ­ć‚­ć‚·ćƒ—ćƒ­ćƒ”ćƒ«ļ¼‰āˆ’ļ¼–āˆ’ćƒ•ćƒ«ć‚Ŗ惭āˆ’ļ¼’āˆ’ļ¼ˆļ¼‘āˆ’ćƒ’ćƒ‰ćƒ­ć‚­ć‚·āˆ’ļ¼’āˆ’ćƒ”ćƒćƒ«ćƒ—ćƒ­ćƒ‘ćƒ³āˆ’ļ¼’āˆ’ć‚¤ćƒ«ļ¼‰āˆ’ļ¼‘ļ½ˆāˆ’ć‚¤ćƒ³ćƒ‰ćƒ¼ćƒ«āˆ’ļ¼•āˆ’ć‚¤ćƒ«ļ¼‰ć‚·ć‚Æćƒ­ćƒ—ćƒ­ćƒ‘ćƒ³ć‚«ćƒ«ćƒœć‚­ć‚µćƒŸćƒ‰ć‚’å«ć‚€åŒ»č–¬ēµ„ęˆē‰©ćŠć‚ˆć³ćć®ęŠ•äøŽ
CN102133402B (zh) * 2011-03-24 2013-06-12 首都医ē§‘大学附属北äŗ¬åŒä»åŒ»é™¢ å›Šę€§ēŗ¤ē»“化č·Øč†œč½¬åÆ¼č°ƒčŠ‚å› å­ęŠ‘åˆ¶å‰‚åœØåˆ¶å¤‡ę²»ē–—ē³–å°æē—…čÆē‰©äø­ēš„åŗ”ē”Ø
WO2013067410A1 (en) 2011-11-02 2013-05-10 Vertex Pharmaceuticals Incorporated Use of (n- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl] - 1, 4 - dihydro - 4 - oxoquinoline - 3 - ca rboxamide) for treating cftr mediated diseases
CA2852991C (en) 2011-11-08 2019-12-31 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
AU2013226076B2 (en) 2012-02-27 2017-11-16 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administration thereof
US8703953B2 (en) 2012-03-09 2014-04-22 Bristol-Myers Squibb Company Aryl ether-base kinase inhibitors
US8674108B2 (en) 2012-04-20 2014-03-18 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
AU2013259294B2 (en) * 2012-05-11 2017-04-06 Synchronicity Pharma, Inc. Carbazole-containing sulfonamides as cryptochrome modulators
AU2013270681A1 (en) 2012-06-08 2014-12-18 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of CFTR -mediated disorders
EP2872122A1 (en) 2012-07-16 2015-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
US8901305B2 (en) 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
CN102816104B (zh) * 2012-08-30 2014-05-21 ęµ™ę±Ÿå¤§å­¦ äø€ē§3-ę°°åŸŗ吲哚ē±»åŒ–合ē‰©ēš„åˆęˆę–¹ę³•
ITMI20122065A1 (it) 2012-12-03 2014-06-04 Univ Padova Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
JP2016509066A (ja) 2013-02-22 2016-03-24 惖ćƒŖć‚¹ćƒˆćƒ«āˆ’ćƒžć‚¤ćƒ¤ćƒ¼ć‚ŗ ć‚¹ć‚Æ悤惖 ć‚«ćƒ³ćƒ‘ćƒ‹ćƒ¼ļ¼¢ļ½’ļ½‰ļ½“ļ½”ļ½ļ½Œāˆ’ļ¼­ļ½™ļ½…ļ½’ļ½“ ļ¼³ļ½‘ļ½•ļ½‰ļ½‚ļ½‚ ļ¼£ļ½ļ½ļ½ļ½ļ½Žļ½™ ć‚¢ćƒ€ćƒ—ć‚æćƒ¼é–¢é€£ć‚­ćƒŠćƒ¼ć‚¼ļ¼‘ļ¼ˆļ½ļ½ļ½‹ļ¼‘ļ¼‰ć®é˜»å®³å‰¤ćØ恗恦恮ļ¼•ļ½ˆāˆ’ć‚Æćƒ­ćƒ”ćƒŽļ¼»ļ¼“ļ¼Œļ¼”āˆ’ļ½ƒļ¼½ćƒ”ćƒŖć‚øćƒ³
US10253027B2 (en) 2013-07-08 2019-04-09 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
US10231932B2 (en) 2013-11-12 2019-03-19 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
TWI690521B (zh) 2014-04-07 2020-04-11 ē¾Žå•†åŒę­„č£½č—„å…¬åø 作ē‚ŗéš±čŠ±č‰²ē“ čŖæēÆ€åŠ‘ä¹‹å«ęœ‰å’”å”‘ä¹‹é†Æčƒŗ锞态čƒŗåŸŗē”²é…øé…Æé”žåŠč„²é”ž
CN103922934B (zh) * 2014-04-11 2016-03-30 北äŗ¬ä¹åØę³°å…‹åŒ»čÆꊀęœÆęœ‰é™å…¬åø ę“»ę³¼äŗšē”²åŸŗ化合ē‰©ēš„ēƒ·åŸŗåŒ–ę–¹ę³•
RU2744460C2 (ru) 2014-04-15 2021-03-09 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚ŠøŠŗŠ°Š»Š· Š˜Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ Š¤Š°Ń€Š¼Š°Ń†ŠµŠ²Ń‚ŠøчŠµŃŠŗŠøŠµ ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠø Š“Š»Ń Š»ŠµŃ‡ŠµŠ½Šøя Š·Š°Š±Š¾Š»ŠµŠ²Š°Š½ŠøŠ¹, Š¾ŠæŠ¾ŃŃ€ŠµŠ“Š¾Š²Š°Š½Š½Ń‹Ń… Š¼ŃƒŠŗŠ¾Š²ŠøсцŠøŠ“Š¾Š·Š½Ń‹Š¼ трŠ°Š½ŃŠ¼ŠµŠ¼Š±Ń€Š°Š½Š½Ń‹Š¼ рŠµŠ³ŃƒŠ»ŃŃ‚Š¾Ń€Š¾Š¼ ŠæрŠ¾Š²Š¾Š“ŠøŠ¼Š¾ŃŃ‚Šø
CN112250627B (zh) 2014-10-06 2024-02-02 弗ē‰¹å…‹ę–ÆčÆå“ęœ‰é™å…¬åø å›Šę€§ēŗ¤ē»“化č·Øč†œč½¬åÆ¼č°ƒčŠ‚å› å­č°ƒčŠ‚å‰‚
JP6746569B2 (ja) 2014-10-07 2020-08-26 ćƒćƒ¼ćƒ†ćƒƒć‚Æć‚¹ ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ļ¼¶ļ½…ļ½’ļ½”ļ½…ļ½˜ ļ¼°ļ½ˆļ½ļ½’ļ½ļ½ļ½ƒļ½…ļ½•ļ½”ļ½‰ļ½ƒļ½ļ½Œļ½“ ļ¼©ļ½Žļ½ƒļ½ļ½’ļ½ļ½ļ½’ļ½ļ½”ļ½…ļ½„ åš¢čƒžę€§ē·šē¶­ē—‡č†œč²«é€šć‚³ćƒ³ćƒ€ć‚Æć‚æćƒ³ć‚¹åˆ¶å¾”å› å­ć®ćƒ¢ć‚øćƒ„ćƒ¬ćƒ¼ć‚æćƒ¼ć®å…±ēµę™¶
ES2830279T3 (es) 2014-10-31 2021-06-03 Abbvie Overseas Sarl Cromanos sustituidos y mƩtodo de uso
SG11201703963QA (en) 2014-11-18 2017-06-29 Vertex Pharma Process of conducting high throughput testing high performance liquid chromatography
WO2016160945A1 (en) 2015-03-31 2016-10-06 Concert Pharmaceuticals, Inc. Deuterated vx-661
EP3292124B1 (en) 2015-04-10 2019-05-22 Bristol-Myers Squibb Company 6h-isochromeno[3,4-c]pyridines and benzo[c][1,7]naphthyridin-6-(5h)-ones as adaptor associated kinase 1 (aak1) inhibitors
CN105153105B (zh) * 2015-08-15 2018-01-19 ęµ™ę±Ÿę°ø宁čÆäøšč‚”ä»½ęœ‰é™å…¬åø 1ā€‘(2,2ā€‘äŗŒę°Ÿč‹Æ并[d][1,3]äŗŒę°§ę‚ēŽÆꈊēƒÆā€‘5ā€‘åŸŗ)ēŽÆäø™ēƒ·ē”²é…øēš„åˆęˆę–¹ę³•åŠå…¶äø­é—“体
RS62670B1 (sr) 2016-09-30 2021-12-31 Vertex Pharma Modulator transmembranskog regulatora provodnosti cistične fibroze, farmaceutske kompozicije, metode lečenja i proces izrade modulatora
MX2019006637A (es) 2016-12-09 2019-08-21 Vertex Pharma Modulador del regulador de conductancia transmembrana de fibrosis quistica composiciones farmaceuticas metodos de tratamiento y proceso para producir el modulador.
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
MA49631A (fr) 2017-07-17 2020-05-27 Vertex Pharma MĆ©thodes de traitement de la fibrose kystique
CA3071278A1 (en) 2017-08-02 2019-02-07 Vertex Pharmaceuticals Incorporated Processes for preparing pyrrolidine compounds
CA3078893A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of cftr modulators
TWI815829B (zh) 2017-11-14 2023-09-21 ē¾Žå•†é»˜ę²™ę±ęœ‰é™č²¬ä»»å…¬åø 作ē‚ŗ吲哚čƒŗ2,3-äŗŒę°§é…¶(ido)ęŠ‘åˆ¶åŠ‘ä¹‹ę–°ē©Žē¶“取代äŗŒčŠ³åŸŗ化合ē‰©
US11498904B2 (en) 2017-11-14 2022-11-15 Merck Sharp & Dohme Llc Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
MX2020005753A (es) 2017-12-08 2020-08-20 Vertex Pharma Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica.
TWI810243B (zh) 2018-02-05 2023-08-01 ē¾Žå•†ē¶­ę³°å…‹ę–Æč£½č—„å…¬åø ē”Øę–¼ę²»ē™‚å›Šč…«ēŗ–化ē—‡ä¹‹é†«č—„ēµ„合ē‰©
US11066417B2 (en) 2018-02-15 2021-07-20 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators
WO2019200246A1 (en) 2018-04-13 2019-10-17 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
HUE066335T2 (hu) 2018-10-05 2024-07-28 Annapurna Bio Inc VegyĆ¼letek Ć©s kĆ©szĆ­tmĆ©nyek APJ receptor aktivitĆ”shoz kapcsolĆ³dĆ³ Ć”llapotok kezelĆ©sĆ©re
CN109880090A (zh) * 2019-02-18 2019-06-14 华ē ”(佛山)ēŗ³ē±³ęę–™ęœ‰é™å…¬åø äø€ē§å«ēŸ³å¢ØēƒÆ仄及ē¢³ēŗ³ē±³ē®”ēš„聚酰äŗščƒŗåƼēƒ­ęę–™ć€åƼēƒ­č†œåŠå…¶åˆ¶å¤‡ę–¹ę³•
TW202120517A (zh) 2019-08-14 2021-06-01 ē¾Žå•†ē¶­ę³°å…‹ę–Æč£½č—„å…¬åø č£½å‚™cftrčŖæēÆ€åŠ‘ä¹‹ę–¹ę³•
MX2022001828A (es) 2019-08-14 2022-06-08 Vertex Pharma Formas cristalinas de moduladores del regulador de conductancia transmembrana de la fibrosis quistica (cftr).
TW202115092A (zh) 2019-08-14 2021-04-16 ē¾Žå•†ē¶­ę³°å…‹ę–Æč£½č—„å…¬åø å›Šč…«ēŗ–ē¶­åŒ–č·Øč†œå‚³å°ŽčŖæēÆ€č›‹ē™½ä¹‹čŖæēƀ劑
CN113748716B (zh) * 2020-03-31 2022-10-28 华äøŗꊀęœÆęœ‰é™å…¬åø 小åŒŗꐜē“¢ēš„ę–¹ę³•ć€č£…ē½®åŠē³»ē»Ÿ
MX2023001993A (es) 2020-08-20 2023-02-27 Univ Leland Stanford Junior Metodos para tratar enfermedades respiratorias caracterizados por hipersecrecion de mucosidad.
CN112851493B (zh) * 2020-11-10 2022-09-06 å°å·žč‡»ęŒšē”Ÿē‰©ē§‘ęŠ€ęœ‰é™å…¬åø äø€ē§2,4,5-äø‰ę°Ÿč‹Æ乙é…øēš„åˆ¶å¤‡ę–¹ę³•
DE102021207925A1 (de) * 2021-07-23 2023-01-26 Continental Reifen Deutschland Gmbh Verbindung, Verfahren zu deren Herstellung sowie Verwendung der Verbindung als Alterungsschutzmittel und/oder Ozonschutzmittel und/oder Farbstoff
WO2024056798A1 (en) 2022-09-15 2024-03-21 Idorsia Pharmaceuticals Ltd Macrocyclic cftr modulators
TW202421102A (zh) 2022-09-15 2024-06-01 ē‘žå£«å•†ę„›ęœč„æäŗžč£½č—„ęœ‰é™å…¬åø å·Øē’°cftrčŖæēÆ€åŠ‘čˆ‡cftrę ”ę­£å­åŠ/ꈖcftrå¢žę•ˆåŠ‘ä¹‹ēµ„合
CN115872895A (zh) * 2023-02-22 2023-03-31 北äŗ¬čÆŗē¦¾č‡“ęŗē§‘ęŠ€č‚”ä»½ęœ‰é™å…¬åø ē”ØäŗŽč”ē”ŸēŸ­é“¾č„‚č‚Ŗé…øę ‡å‡†å“ä½œäøŗå†…ę ‡ēš„é‡ę ‡čÆ•å‰‚åŠå…¶åˆ¶å¤‡ę–¹ę³•ć€åŗ”ē”Ø

Family Cites Families (174)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5328173A (en) 1976-08-06 1978-03-16 Zenyaku Kogyo Kk Novel phenylmethanenitro compound and its preparation
US4138397A (en) 1978-02-27 1979-02-06 Richardson-Merrell Inc. 6-(2,3-Dihydro-5-benzofuranyl)acetamido penicillin derivatives
GB8524157D0 (en) * 1984-10-19 1985-11-06 Ici America Inc Heterocyclic amides
JPS61103861A (ja) 1984-10-27 1986-05-22 Nitto Kasei Kk ć‚¢ćƒŖāˆ’ćƒ«ē½®ę›ć‚·ć‚¢ćƒ³é…¢é…øć‚Øć‚¹ćƒ†ćƒ«ć®č£½é€ ę–¹ę³•
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
GB9005014D0 (en) * 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
GB9317764D0 (en) 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
US5510379A (en) 1994-12-19 1996-04-23 Warner-Lambert Company Sulfonate ACAT inhibitors
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
WO1998047868A1 (en) 1997-04-18 1998-10-29 Smithkline Beecham Plc Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists
JP2002504916A (ja) 1997-06-21 2002-02-12 ćƒ­ć‚·ćƒ„ ćƒ€ć‚¤ć‚¢ć‚°ćƒŽć‚¹ćƒ†ć‚£ć‚Æć‚¹ ć‚²ć‚¼ćƒ«ć‚·ćƒ£ćƒ•ćƒˆ 惟惃惈 ćƒ™ć‚·ćƒ„ćƒ¬ćƒ³ć‚Æćƒ†ćƒ« ćƒćƒ•ćƒ„ćƒ³ć‚° ęŠ—č»¢ē§»åŠć³ęŠ—č…«ē˜ę“»ę€§ć‚’ęœ‰ć™ć‚‹ćƒćƒ«ćƒ“ćƒ„ćƒ¼ćƒ«é…øčŖ˜å°Žä½“
ATE364374T1 (de) 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhƶhter bioverfĆ¼gbarkeit
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US6426331B1 (en) 1998-07-08 2002-07-30 Tularik Inc. Inhibitors of STAT function
EP1035115B1 (en) 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
WO2001019830A1 (en) 1999-09-10 2001-03-22 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
IT1315267B1 (it) 1999-12-23 2003-02-03 Novuspharma Spa Derivati di 2-(1h-indol-3-il)-2-oxo-acetammidi ad attivita'antitumorale
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
CA2402174A1 (en) * 2000-03-09 2001-09-13 Ono Pharmaceutical Co., Ltd. Indole derivatives, process for preparation of the same and use thereof
DE10038019A1 (de) 2000-08-04 2002-02-14 Bayer Ag Substituierte Triazolopyrid(az)ine
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6562989B2 (en) 2000-08-07 2003-05-13 Yale University Catalyst for aromatic Cā€”O, Cā€”N, and Cā€”C bond formation
TWI259180B (en) 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
AR030357A1 (es) 2000-08-18 2003-08-20 Lundbeck & Co As H Derivados 4 -, 5 -, 6 - y 7-indol
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
AU2002258794A1 (en) 2001-04-10 2003-10-20 Transtech Pharma, Inc. Probes, systems and methods for drug discovery
US6982274B2 (en) 2001-04-16 2006-01-03 Eisai Co., Ltd. 1H-indazole compound
CN1880304B (zh) * 2001-06-28 2010-11-24 č¾‰ē‘žäŗ§å“å…¬åø äø‰é…°čƒŗ取代ēš„å²å“šć€č‹Æ并呋喃及č‹Æ并噻吩
US6841566B2 (en) 2001-07-20 2005-01-11 Boehringer Ingelheim, Ltd. Viral polymerase inhibitors
JP2005518391A (ja) 2001-12-21 2005-06-23 ćƒŽćƒœć€€ćƒŽćƒ«ćƒ‡ć‚£ć‚¹ć‚Æć€€ć‚¢ć‚Æćƒ†ć‚£ćƒ¼ć‚¼ćƒ«ć‚¹ć‚«ćƒ– ļ¼§ļ½‹ę“»ę€§åŒ–剤ćØć—ć¦ć®ć‚¢ćƒŸćƒ‰čŖ˜å°Žä½“
WO2004007472A1 (ja) 2002-07-10 2004-01-22 Ono Pharmaceutical Co., Ltd. ļ¼£ļ½ƒļ½’ļ¼”ć‚¢ćƒ³ć‚æć‚“ćƒ‹ć‚¹ćƒˆćŠć‚ˆć³ćć®åŒ»č–¬ē”Ø途
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
US20060083784A1 (en) 2002-08-07 2006-04-20 Smithkline Beecham Corporation Amorphous pharmaceutical compositions
PL376147A1 (en) 2002-09-30 2005-12-27 The Regents Of The University Of California Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
JP2004131393A (ja) 2002-10-08 2004-04-30 Kowa Co ꘓęŗ¶å‡ŗę€§č£½å‰¤
JP4227389B2 (ja) * 2002-10-09 2009-02-18 ęµœę¾ćƒ›ćƒˆćƒ‹ć‚Æć‚¹ę Ŗ式会ē¤¾ ę’®åƒč£…ē½®åŠć³ćć®č£½é€ ę–¹ę³•
AU2003287160A1 (en) * 2002-10-15 2004-05-04 Rigel Pharmaceuticals, Inc. Substituted indoles and their use as hcv inhibitors
FR2846327B1 (fr) 2002-10-25 2006-03-24 Merck Sante Sas Derives de n-benzodioxolyl, n-benzodioxanyl et n-benzodioxepinyl arylcarboxamides utilisables dans le traitement de dyslipidemies et compositions pharmaceutiques les contenant.
US7622592B2 (en) * 2002-11-01 2009-11-24 Merck & Co., Inc. Carbonylamino-benzimidazole derivatives as androgen receptor modulators
WO2004056744A1 (en) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
DE10306941A1 (de) 2003-02-18 2004-08-26 Merck Patent Gmbh Benzofuranoxyethylamine
US20050113423A1 (en) * 2003-03-12 2005-05-26 Vangoor Frederick F. Modulators of ATP-binding cassette transporters
MXPA05010444A (es) 2003-04-03 2005-11-04 Merck Patent Gmbh Compuestos de carbonilo.
UA84420C2 (ru) 2003-04-11 2008-10-27 ŠŸŠøŠ¢ŠøŠ”Šø Š¢Š•Š ŠŠŸŠ¬Š®Š¢Š˜ŠšŠ”, Š˜ŠŠš. Š”ŠžŠ•Š”Š˜ŠŠ•ŠŠ˜ŠÆ 1,2,4-ŠžŠšŠ”ŠŠ”Š˜ŠŠ—ŠžŠ›Š‘Š•ŠŠ—ŠžŠ™ŠŠžŠ™ ŠšŠ˜Š”Š›ŠžŠ¢Š«, Š¤ŠŠ ŠœŠŠ¦Š•Š’Š¢Š˜Š§Š•Š”ŠšŠŠÆ ŠšŠžŠœŠŸŠžŠ—Š˜Š¦Š˜ŠÆ (Š’ŠŠ Š˜ŠŠŠ¢Š«) Š˜ ŠŸŠ Š˜ŠœŠ•ŠŠ•ŠŠ˜Š• Š”ŠžŠ•Š”Š˜ŠŠ•ŠŠ˜Š™ Š”Š›ŠÆ Š›Š•Š§Š•ŠŠ˜ŠÆ Š—ŠŠ‘ŠžŠ›Š•Š’ŠŠŠ˜ŠÆ, Š”Š’ŠÆŠ—ŠŠŠŠžŠ“Šž Š” ŠŸŠ Š•Š–Š”Š•Š’Š Š•ŠœŠ•ŠŠŠžŠ™ Š¢Š•Š ŠœŠ˜ŠŠŠ¦Š˜Š•Š™ Š¢Š ŠŠŠ”Š›ŠÆŠ¦Š˜Š˜ Š˜Š›Š˜ ŠŠžŠŠ”Š•ŠŠ”-ŠžŠ‘Š£Š”Š›ŠžŠ’Š›Š•ŠŠŠ«Šœ Š£ŠœŠ•ŠŠ¬ŠØŠ•ŠŠ˜Š•Šœ Š¼Š ŠŠš
US7696244B2 (en) 2003-05-16 2010-04-13 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
DE602004022819D1 (de) * 2003-06-06 2009-10-08 Vertex Pharma Von atp-bindende kassette transportern
CA2530075C (en) 2003-06-27 2012-08-21 Harvey Pollard Amphiphilic pyridinium compounds, method of making and use thereof
CA2535646C (en) * 2003-08-15 2010-08-10 H. Lundbeck A/S Cyclopropyl derivatives as nk3 receptor antagonists
ZA200601175B (en) * 2003-08-15 2007-04-25 Lundbeck & Co As H Cyclopropyl derivatives as NK3 receptor antagonists
MXPA06002567A (es) 2003-09-06 2006-09-04 Vertex Pharma Moduladores de transportadores con casete de union de atp.
US20050070718A1 (en) 2003-09-30 2005-03-31 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
KR20060121909A (ko) 2003-10-08 2006-11-29 ė²„ķ…ģŠ¤ ķŒŒė§ˆģŠˆķ‹°ģ¹¼ģŠ¤ ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ģ‚¬ģ“ķ“ė”œģ•Œķ‚¬ ė˜ėŠ” ķ”¼ė¼ė‹ ź·øė£¹ģ„ ķ¬ķ•Øķ•˜ėŠ” ļ½ļ½”ļ½-ź²°ķ•©ģ¹“ģ„øķŠø ģˆ˜ģ†”ģžģ˜ ģ”°ģ ˆģž
WO2005037802A1 (ja) 2003-10-16 2005-04-28 Sankyo Company, Limited ļ¼•ļ¼ć‚¢ćƒŖćƒ¼ćƒ«ćƒ”ćƒŖ惟ć‚øćƒ³čŖ˜å°Žä½“
JPWO2005040135A1 (ja) 2003-10-24 2007-03-08 å°é‡Žč–¬å“å·„ę„­ę Ŗ式会ē¤¾ ęŠ—ć‚¹ćƒˆćƒ¬ć‚¹č–¬ćŠć‚ˆć³ćć®åŒ»č–¬ē”Ø途
ES2328824T3 (es) * 2003-11-14 2009-11-18 Vertex Pharmaceuticals Incorporated Tiazoles y oxazoles utiles como moduladores de transportadores de tipo casete de union a atp.
GB0330043D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2005075435A1 (en) * 2004-01-30 2005-08-18 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
JP4896745B2 (ja) 2004-02-02 2012-03-14 ć‚¢ćƒ³ćƒ–ćƒ¬ćƒ„ć‚Æć‚¹ćƒ»ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒ„ćƒ‰ äæ®é£¾ć•ć‚ŒćŸćƒ’ćƒˆć‚¤ćƒ³ć‚æćƒ¼ćƒ•ć‚§ćƒ­ćƒ³ćƒćƒŖćƒšćƒ—ćƒćƒ‰ćŠć‚ˆć³ć“ć‚Œć‚‰ć®ä½æē”Ø
AU2005228685B2 (en) 2004-03-30 2010-08-19 The Regents Of The University Of California Hydrazide-containing CFTR inhibitor compounds and uses thereof
US20050222271A1 (en) 2004-03-31 2005-10-06 Le Huang Novel amorphous form of memantine hydrochloride
AU2005249154B2 (en) 2004-06-01 2011-02-10 Luminex Molecular Diagnostics, Inc. Method of detecting cystic fibrosis associated mutations
CA2569402A1 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
ES2656017T3 (es) 2004-06-24 2018-02-22 Vertex Pharmaceuticals Incorporated Moduladores de transportadores del casete de uniĆ³n a ATP
US20140343098A1 (en) 2004-06-24 2014-11-20 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
US20060000401A1 (en) 2004-07-01 2006-01-05 Massetti Joseph A Mooring line storage device
JP2008505124A (ja) 2004-07-02 2008-02-21 ć‚¢ćƒ‰ćƒćƒ³ć‚·ć‚¹ ćƒ•ć‚”ćƒ¼ćƒžć‚¹ćƒ¼ćƒ†ć‚£ć‚«ćƒ« ć‚³ćƒ¼ćƒćƒ¬ć‚¤ć‚·ćƒ§ćƒ³ ćƒ‘ćƒ«ć‚¹é€é”ē”Ø錠剤
CA2573223C (en) 2004-08-06 2013-05-21 Otsuka Pharmaceutical Co., Ltd. Aromatic compound
DE102004047254A1 (de) 2004-09-29 2006-04-13 Merck Patent Gmbh Carbonylverbindungen
EP3067053A1 (en) 2004-10-13 2016-09-14 PTC Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
CA2599348C (en) 2005-02-25 2013-07-23 Ono Pharmaceutical Co., Ltd. Indole compound and use thereof
US8242149B2 (en) 2005-03-11 2012-08-14 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
WO2006101740A2 (en) 2005-03-18 2006-09-28 The Regents Of The University Of California Compounds having activity in correcting mutant-cftr processing and uses thereof
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
PT2348022E (pt) 2005-03-28 2013-02-13 Toyama Chemical Co Ltd Processo para a produĆ§Ć£o de 1-(3-(2-(1- benzotiofen-5-il)etoxi)propil)azetidin-3-ol ou dos seus sais
JP5800451B2 (ja) 2005-04-08 2015-10-28 ćƒ”ćƒ¼ćƒ†ć‚£ćƒ¼ć‚·ćƒ¼ ć‚»ćƒ©ćƒ”ćƒ„ćƒ¼ćƒ†ć‚£ć‚Æć‚¹ļ¼Œć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ćƒ¼ćƒ†ćƒƒćƒ‰ ćƒŠćƒ³ć‚»ćƒ³ć‚¹ēŖē„¶å¤‰ē•°ęŠ‘åˆ¶ę²»ē™‚ē”Ø恮态ēµŒå£ēš„恫ꓻꀧćŖļ¼‘ļ¼Œļ¼’ļ¼Œļ¼”āˆ’ć‚Ŗ悭悵ć‚øć‚¢ć‚¾ćƒ¼ćƒ«ēµ„ęˆē‰©
EP1891018B1 (en) * 2005-05-24 2011-11-16 Vertex Pharmaceuticals, Inc. Modulators of atp-binding cassette transporters
CN101287732A (zh) 2005-08-11 2008-10-15 ę²ƒę³°å…‹ę–ÆčÆē‰©č‚”ä»½ęœ‰é™å…¬åø å›Šę€§ēŗ¤ē»“化č·Ø膜ē”µåÆ¼č°ƒčŠ‚å‰‚ēš„č°ƒęŽ§å‰‚
KR20080053297A (ko) 2005-08-11 2008-06-12 ė²„ķ…ģŠ¤ ķŒŒė§ˆģŠˆķ‹°ģ¹¼ģŠ¤ ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ė‚­ķ¬ģ„± ģ„¬ģœ ģ¢… ķŠøėžœģŠ¤ė§‰ ģ „ė„ė„ ģ”°ģ •ģžģ˜ ģ”°ģ ˆģž
NZ566313A (en) 2005-08-29 2011-04-29 Sanofi Aventis Us Llc Amorphous solid dispersions of 7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4, 5-b]indole-1-acetamide
US8314256B2 (en) 2005-10-06 2012-11-20 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7401405B2 (en) * 2005-10-11 2008-07-22 Silverbrook Research Pty Ltd Method of fabricating inkjet nozzles having associated ink priming features
EP1945632B1 (en) 2005-11-08 2013-09-18 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
US20120232059A1 (en) * 2005-11-08 2012-09-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette Transporters
ME02736B (me) 2005-12-21 2017-10-20 Janssen Pharmaceutica Nv Triazolopiridazini kao modulatori tirozin kinaze
WO2007075901A2 (en) 2005-12-24 2007-07-05 Vertex Pharmaceuticals Incorporated Quinolin- 4 - one derivatives as modulators of abc transporters
CA2635214A1 (en) 2005-12-27 2007-07-05 Vertex Pharmaceuticals Incorporated Compounds useful in cftr assays and methods therewith
EP2016065B1 (en) * 2005-12-28 2012-09-19 Vertex Pharmaceuticals Incorporated 1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropane-carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensƦtninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
TW201414469A (zh) 2006-03-20 2014-04-16 Vertex Pharma å°åŒ…ę‹¬ļ½–ļ½˜-ļ¼™ļ¼•ļ¼ä¹‹č—„ē‰©åÆ¦ę–½å™“éœ§ä¹¾ē‡„ä¹‹ę–¹ę³•åŠē”±ę­¤ę–¹ę³•č£½å‚™ä¹‹ē”¢ē‰©
JP2009530415A (ja) 2006-03-20 2009-08-27 ćƒćƒ¼ćƒ†ćƒƒć‚Æć‚¹ ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ åŒ»č–¬ēµ„ęˆē‰©
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
CA2869945C (en) 2006-04-07 2018-01-23 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
ES2377840T3 (es) * 2006-05-12 2012-04-02 Vertex Pharmaceuticals, Inc. Composiciones de N-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida
ES2393132T3 (es) 2006-10-23 2012-12-18 Sgx Pharmaceuticals, Inc. Moduoladores de proteĆ­na quinasa de triazolopiridazina
US8563573B2 (en) * 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
ES2646175T3 (es) 2006-11-03 2017-12-12 Vertex Pharmaceuticals Incorporated Derivados de azaindol como moduladores de CFTR
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
WO2008064259A2 (en) 2006-11-21 2008-05-29 Biokey, Inc. Solid dispersion composition comprising fluvastatin
JPWO2008065732A1 (ja) 2006-11-27 2010-03-04 ę—„ęœ¬ćƒćƒŖć‚¦ćƒ¬ć‚æćƒ³å·„ę„­ę Ŗ式会ē¤¾ ć‚¢ćƒ­ćƒ•ć‚”ćƒćƒ¼ćƒˆēµåˆåŠć³ć‚¤ć‚½ć‚·ć‚¢ćƒŒćƒ¬ćƒ¼ćƒˆēµåˆå«ęœ‰å¤‰ę€§ć‚¤ć‚½ć‚·ć‚¢ćƒćƒ¼ćƒˆę··åˆē‰©ć®č£½é€ ę–¹ę³•
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
EP2789606B1 (en) 2007-05-09 2017-11-15 Vertex Pharmaceuticals Incorporated Modulators of CFTR
EP2170901B1 (en) 2007-05-25 2015-07-01 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US20110177999A1 (en) * 2007-08-09 2011-07-21 Vertex Pharmaceuticals Incorporated Therapeutic Combinations Useful in Treating CFTR Related Diseases
CA2696298C (en) 2007-08-24 2016-09-06 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
NZ583878A (en) 2007-09-14 2012-10-26 Vertex Pharma Modulators of ABC transporter and cystic fibrosis transmembrane conductance regulator (CFTR)
CA2699292A1 (en) * 2007-09-14 2009-03-26 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
EP3012250B1 (en) 2007-11-16 2017-11-08 Vertex Pharmaceuticals Incorporated Isoquinoline modulators of atp-binding cassette transporters
TWI482768B (zh) 2007-11-22 2015-05-01 Zenyaku Kogyo Kk 雜ē’°åŒ–合ē‰©ä¹‹éžę™¶č³Ŗé«”ć€å«ęœ‰å…¶ä¹‹å›ŗé«”åˆ†ę•£é«”ć€č—„åŠ‘åŠå…¶č£½ę³•
JP2011506331A (ja) * 2007-12-07 2011-03-03 ćƒćƒ¼ćƒ†ćƒƒć‚Æć‚¹ ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ļ¼“āˆ’ļ¼ˆļ¼–āˆ’ļ¼ˆļ¼‘āˆ’ļ¼ˆļ¼’ļ¼Œļ¼’āˆ’ć‚øćƒ•ćƒ«ć‚Ŗćƒ­ćƒ™ćƒ³ć‚¾ļ¼»ļ½„ļ¼½ļ¼»ļ¼‘ļ¼Œļ¼“ļ¼½ć‚øć‚Ŗć‚­ć‚½ćƒ¼ćƒ«āˆ’ļ¼•āˆ’ć‚¤ćƒ«ļ¼‰ć‚·ć‚Æćƒ­ćƒ—ćƒ­ćƒ‘ćƒ³ć‚«ćƒ«ćƒœć‚­ć‚µćƒŸćƒ‰ļ¼‰āˆ’ļ¼“āˆ’ćƒ”ćƒćƒ«ćƒ”ćƒŖć‚øćƒ³āˆ’ļ¼’āˆ’ć‚¤ćƒ«ļ¼‰å®‰ęÆ香é…øć®å‡¦ę–¹ē‰©
NZ612635A (en) 2007-12-07 2015-06-26 Vertex Pharma Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
US20100036130A1 (en) * 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
EP3683218B1 (en) 2007-12-07 2024-09-18 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
AU2008335031B2 (en) 2007-12-13 2013-11-28 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CA2931134C (en) 2008-02-28 2019-07-30 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as cftr modulators
SI2615085T1 (sl) * 2008-03-31 2015-11-30 Vertex Pharmaceuticals Incorporated Piridilni derivati kot cftr-modulatorji
CA2722371C (en) 2008-04-24 2016-06-21 Bristol-Myers Squibb Company Use of epothelone d in treating tau-associated diseases including alzheimer's disease
US20100256184A1 (en) 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
ME03019B (me) 2008-08-13 2018-10-20 Vertex Pharma Farmaceutska kompozicija n-[2,4-bis(1,1- dimeтileтil)-5-hidroksifenil]- 1,4-dihidro-4-oksohinolin-3-karboksamida i njeno ordiniranje
JP2012504143A (ja) * 2008-09-29 2012-02-16 ćƒćƒ¼ćƒ†ćƒƒć‚Æć‚¹ ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ļ¼“āˆ’ļ¼ˆļ¼–āˆ’ļ¼ˆļ¼‘āˆ’ļ¼ˆļ¼’ļ¼Œļ¼’āˆ’ć‚øćƒ•ćƒ«ć‚Ŗćƒ­ćƒ™ćƒ³ć‚¾ļ¼»ļ½„ļ¼½ļ¼»ļ¼‘ļ¼Œļ¼“ļ¼½ć‚øć‚Ŗć‚­ć‚½ćƒ¼ćƒ«āˆ’ļ¼•āˆ’ć‚¤ćƒ«ļ¼‰ć‚·ć‚Æćƒ­ćƒ—ćƒ­ćƒ‘ćƒ³ć‚«ćƒ«ćƒœć‚­ć‚µćƒŸćƒ‰ļ¼‰āˆ’ļ¼“āˆ’ćƒ”ćƒćƒ«ćƒ”ćƒŖć‚øćƒ³āˆ’ļ¼’āˆ’ć‚¤ćƒ«ļ¼‰å®‰ęÆ香é…ø恮ē”Ø量単位
NZ592687A (en) 2008-10-23 2013-04-26 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
MX2011004374A (es) * 2008-10-23 2011-05-23 Vertex Pharma Formas solidas de n-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2-(trifluo rometil)fenil)-4-oxo-5-(trifluorometil)-1,4-dihidroquinolin-3-car boxamida.
US20110257223A1 (en) * 2008-10-23 2011-10-20 Vertex Pharmaceuticals Incorporated Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
BRPI0919930A2 (pt) * 2008-10-23 2016-02-16 Vertex Pharma moduladores de regulador de condutĆ¢ncia transmembrana de fibrose cĆ­stica
NZ592694A (en) 2008-11-06 2013-05-31 Vertex Pharma ATP-Binding Cassette (ABC) transporters as modulators of CFTR activity
UA104876C2 (uk) 2008-11-06 2014-03-25 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚Ń–ŠŗŠ°Š»Š· Š†Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ ŠœŠ¾Š“уŠ»ŃŃ‚Š¾Ń€Šø atф-Š·Š²'яŠ·ŃƒŠ²Š°Š»ŃŒŠ½Šøх ŠŗŠ°ŃŠµŃ‚Š½Šøх трŠ°Š½ŃŠæŠ¾Ń€Ń‚ŠµŃ€Ń–Š²
US8367660B2 (en) * 2008-12-30 2013-02-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP3330255B1 (en) 2009-03-20 2020-12-09 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
CA2755969C (en) 2009-03-20 2018-05-08 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
RU2543622C2 (ru) 2009-09-17 2015-03-10 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚ŠøŠŗŠ°Š»Š· Š˜Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ Š”ŠæŠ¾ŃŠ¾Š± ŠæŠ¾Š»ŃƒŃ‡ŠµŠ½Šøя Š°Š·Š°Š±ŠøцŠøŠŗŠ»ŠøчŠµŃŠŗŠøх сŠ¾ŠµŠ“ŠøŠ½ŠµŠ½ŠøŠ¹
CA2777245A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
JP5789611B2 (ja) * 2009-10-23 2015-10-07 ćƒćƒ¼ćƒ†ćƒƒć‚Æć‚¹ ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ļ¼¶ļ½…ļ½’ļ½”ļ½…ļ½˜ ļ¼°ļ½ˆļ½ļ½’ļ½ļ½ļ½ƒļ½…ļ½•ļ½”ļ½‰ļ½ƒļ½ļ½Œļ½“ ļ¼©ļ½Žļ½ƒļ½ļ½’ļ½ļ½ļ½’ļ½ļ½”ļ½…ļ½„ åš¢čƒžę€§ē·šē¶­ē—‡č†œć‚³ćƒ³ćƒ€ć‚Æć‚æćƒ³ć‚¹åˆ¶å¾”å› å­ć®ćƒ¢ć‚øćƒ„ćƒ¬ćƒ¼ć‚æćƒ¼ć‚’čŖæč£½ć™ć‚‹ćŸć‚ć®ćƒ—ćƒ­ć‚»ć‚¹
JP5877157B2 (ja) * 2009-10-23 2016-03-02 ćƒćƒ¼ćƒ†ćƒƒć‚Æć‚¹ ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ļ¼¶ļ½…ļ½’ļ½”ļ½…ļ½˜ ļ¼°ļ½ˆļ½ļ½’ļ½ļ½ļ½ƒļ½…ļ½•ļ½”ļ½‰ļ½ƒļ½ļ½Œļ½“ ļ¼©ļ½Žļ½ƒļ½ļ½’ļ½ļ½ļ½’ļ½ļ½”ļ½…ļ½„ ļ¼®āˆ’ļ¼ˆļ¼”āˆ’ļ¼ˆļ¼—āˆ’ć‚¢ć‚¶ćƒ“ć‚·ć‚Æ惭ļ¼»ļ¼’ļ¼Žļ¼’ļ¼Žļ¼‘ļ¼½ćƒ˜ćƒ—ć‚æćƒ³āˆ’ļ¼—āˆ’ć‚¤ćƒ«ļ¼‰āˆ’ļ¼’āˆ’ļ¼ˆćƒˆćƒŖćƒ•ćƒ«ć‚Ŗ惭惔惁惫ļ¼‰ćƒ•ć‚§ćƒ‹ćƒ«ļ¼‰āˆ’ļ¼”āˆ’ć‚Ŗć‚­ć‚½āˆ’ļ¼•āˆ’ļ¼ˆćƒˆćƒŖćƒ•ćƒ«ć‚Ŗ惭惔惁惫ļ¼‰āˆ’ļ¼‘ļ¼Œļ¼”āˆ’ć‚ø惒惉惭悭惎ćƒŖćƒ³āˆ’ļ¼“āˆ’ć‚«ćƒ«ćƒœć‚­ć‚µćƒŸćƒ‰ć®å›ŗä½“å½¢ę…‹
WO2011116397A1 (en) 2010-03-19 2011-09-22 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
HUE062892T2 (hu) 2010-03-25 2023-12-28 Vertex Pharma (R)-1(2,2-difluorbenzo[d][1,3]dioxol-5-il)-N-(1-(2,3-dihidroxipropil)-6-fluor-2-(1-hidroxi- 2-metilpropƔn-2-il)-1H-indol-5-il)ciklopropƔnkarboxamid elƵƔllƭtƔsa Ʃs kƶztitermƩkei
HRP20211752T1 (hr) 2010-04-07 2022-02-18 Vertex Pharmaceuticals Incorporated Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
MX2012011655A (es) 2010-04-07 2012-11-23 Vertex Pharma Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo [d][1-3]dioxol-5-il]ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico.
AU2011242452A1 (en) 2010-04-22 2012-11-08 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
ES2858351T3 (es) 2010-04-22 2021-09-30 Vertex Pharma Compuesto intermedio para proceso de producciĆ³n de compuestos de cicloalquilcaraboxamido-indol
NZ603043A (en) 2010-04-22 2015-02-27 Vertex Pharma Pharmaceutical compositions comprising cftr modulators and administrations thereof
WO2011133956A1 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
EP2787043B1 (fr) 2010-04-30 2018-03-21 Total Marketing Services Utilisation de dƩrivƩs organogelateurs dans des compositions bitumineuses pour amƩliorer leur rƩsistance aux agressions chimiques
NZ603386A (en) * 2010-05-20 2015-02-27 Vertex Pharma Pharmaceutical compositions and administrations thereof
TW201202250A (en) 2010-05-20 2012-01-16 Vertex Pharma Processes for producing modulators of cystic fibrosis transmembrane conductance regulator
US8563593B2 (en) * 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
JP2013536231A (ja) * 2010-08-23 2013-09-19 ćƒćƒ¼ćƒ†ćƒƒć‚Æć‚¹ ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ ļ¼ˆļ½’ļ¼‰āˆ’ļ¼‘āˆ’ļ¼ˆļ¼’ļ¼Œļ¼’āˆ’ć‚øćƒ•ćƒ«ć‚Ŗćƒ­ćƒ™ćƒ³ć‚¾ļ¼»ļ½„ļ¼½ļ¼»ļ¼‘ļ¼Œļ¼“ļ¼½ć‚øć‚Ŗć‚­ć‚½ćƒ¼ćƒ«āˆ’ļ¼•āˆ’ć‚¤ćƒ«ļ¼‰āˆ’ļ½Žāˆ’ļ¼ˆļ¼‘āˆ’ļ¼ˆļ¼’ļ¼Œļ¼“āˆ’ć‚øćƒ’ćƒ‰ćƒ­ć‚­ć‚·ćƒ—ćƒ­ćƒ”ćƒ«ļ¼‰āˆ’ļ¼–āˆ’ćƒ•ćƒ«ć‚Ŗ惭āˆ’ļ¼’āˆ’ļ¼ˆļ¼‘āˆ’ćƒ’ćƒ‰ćƒ­ć‚­ć‚·āˆ’ļ¼’āˆ’ćƒ”ćƒćƒ«ćƒ—ćƒ­ćƒ‘ćƒ³āˆ’ļ¼’āˆ’ć‚¤ćƒ«ļ¼‰āˆ’ļ¼‘ļ½ˆāˆ’ć‚¤ćƒ³ćƒ‰ćƒ¼ćƒ«āˆ’ļ¼•āˆ’ć‚¤ćƒ«ļ¼‰ć‚·ć‚Æćƒ­ćƒ—ćƒ­ćƒ‘ćƒ³ć‚«ćƒ«ćƒœć‚­ć‚µćƒŸćƒ‰ć‚’å«ć‚€åŒ»č–¬ēµ„ęˆē‰©ćŠć‚ˆć³ćć®ęŠ•äøŽ
JP2013536251A (ja) 2010-08-27 2013-09-19 ćƒćƒ¼ćƒ†ćƒƒć‚Æć‚¹ ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ č–¬å­¦ēš„ēµ„ęˆē‰©ćŠć‚ˆć³ćć®ęŠ•äøŽ
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
WO2013067410A1 (en) 2011-11-02 2013-05-10 Vertex Pharmaceuticals Incorporated Use of (n- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl] - 1, 4 - dihydro - 4 - oxoquinoline - 3 - ca rboxamide) for treating cftr mediated diseases
US20140127901A1 (en) 2012-11-08 2014-05-08 Taiwan Semiconductor Manufacturing Company, Ltd. Low-k damage free integration scheme for copper interconnects
CA2852991C (en) * 2011-11-08 2019-12-31 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
SG10201606135TA (en) 2012-01-25 2016-09-29 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
AU2013226076B2 (en) 2012-02-27 2017-11-16 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administration thereof
US8674108B2 (en) 2012-04-20 2014-03-18 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
AU2013270681A1 (en) 2012-06-08 2014-12-18 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of CFTR -mediated disorders
EP2872122A1 (en) 2012-07-16 2015-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
SI2914248T2 (sl) 2012-11-02 2023-12-29 Vertex Pharmaceuticals Incorporated, Farmacevtski sestavki za zdravljenje bolezni, pri katerih posreduje CFTR
US20140221424A1 (en) 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
US20160151335A1 (en) 2013-06-26 2016-06-02 Proteostasis Therapeutics, Inc. Methods of modulating cftr activity
US10231932B2 (en) 2013-11-12 2019-03-19 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
SI3087989T1 (sl) 2013-12-27 2019-03-29 Chugai Seiyaku Kabushiki Kaisha Trdni pripravki, ki vsebujejo tofogliflozin in postopek njihove izdelave
RU2744460C2 (ru) 2014-04-15 2021-03-09 Š’ŠµŃ€Ń‚ŠµŠŗс Š¤Š°Ń€Š¼Š°ŃŃŒŃŽŃ‚ŠøŠŗŠ°Š»Š· Š˜Š½ŠŗŠ¾Ń€ŠæŠ¾Ń€ŠµŠ¹Ń‚ŠµŠ“ Š¤Š°Ń€Š¼Š°Ń†ŠµŠ²Ń‚ŠøчŠµŃŠŗŠøŠµ ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠø Š“Š»Ń Š»ŠµŃ‡ŠµŠ½Šøя Š·Š°Š±Š¾Š»ŠµŠ²Š°Š½ŠøŠ¹, Š¾ŠæŠ¾ŃŃ€ŠµŠ“Š¾Š²Š°Š½Š½Ń‹Ń… Š¼ŃƒŠŗŠ¾Š²ŠøсцŠøŠ“Š¾Š·Š½Ń‹Š¼ трŠ°Š½ŃŠ¼ŠµŠ¼Š±Ń€Š°Š½Š½Ń‹Š¼ рŠµŠ³ŃƒŠ»ŃŃ‚Š¾Ń€Š¾Š¼ ŠæрŠ¾Š²Š¾Š“ŠøŠ¼Š¾ŃŃ‚Šø
CN112250627B (zh) 2014-10-06 2024-02-02 弗ē‰¹å…‹ę–ÆčÆå“ęœ‰é™å…¬åø å›Šę€§ēŗ¤ē»“化č·Øč†œč½¬åÆ¼č°ƒčŠ‚å› å­č°ƒčŠ‚å‰‚
JP6746569B2 (ja) 2014-10-07 2020-08-26 ćƒćƒ¼ćƒ†ćƒƒć‚Æć‚¹ ćƒ•ć‚”ćƒ¼ćƒžć‚·ćƒ„ćƒ¼ćƒ†ć‚£ć‚«ćƒ«ć‚ŗ ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ć‚¤ćƒ†ćƒƒćƒ‰ļ¼¶ļ½…ļ½’ļ½”ļ½…ļ½˜ ļ¼°ļ½ˆļ½ļ½’ļ½ļ½ļ½ƒļ½…ļ½•ļ½”ļ½‰ļ½ƒļ½ļ½Œļ½“ ļ¼©ļ½Žļ½ƒļ½ļ½’ļ½ļ½ļ½’ļ½ļ½”ļ½…ļ½„ åš¢čƒžę€§ē·šē¶­ē—‡č†œč²«é€šć‚³ćƒ³ćƒ€ć‚Æć‚æćƒ³ć‚¹åˆ¶å¾”å› å­ć®ćƒ¢ć‚øćƒ„ćƒ¬ćƒ¼ć‚æćƒ¼ć®å…±ēµę™¶
SG11201703963QA (en) 2014-11-18 2017-06-29 Vertex Pharma Process of conducting high throughput testing high performance liquid chromatography
WO2016086136A1 (en) 2014-11-26 2016-06-02 Catabasis Pharmaceuticals, Inc. Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders
MA41031A (fr) 2014-11-26 2017-10-03 Catabasis Pharmaceuticals Inc ConjuguƩs cystƩamine-acide gras et leur utilisation comme activateurs de l'autophagie
WO2016160945A1 (en) 2015-03-31 2016-10-06 Concert Pharmaceuticals, Inc. Deuterated vx-661
US20180280349A1 (en) 2017-03-28 2018-10-04 Vertex Pharmaceuticals Incorporated Methods of treating cystic fibrosis in patients with residual function mutations

Also Published As

Publication number Publication date
US8912199B2 (en) 2014-12-16
US20150119441A1 (en) 2015-04-30
US10975061B2 (en) 2021-04-13
ES2659364T3 (es) 2018-03-15
ES2580803T3 (es) 2016-08-26
US20180162842A1 (en) 2018-06-14
DK2007756T3 (en) 2015-10-05
US10239867B2 (en) 2019-03-26
JP5420395B2 (ja) 2014-02-19
HUE055205T2 (hu) 2021-11-29
BRPI0710965B8 (pt) 2021-05-25
CN103254177A (zh) 2013-08-21
US20160332997A1 (en) 2016-11-17
DK2674428T3 (en) 2016-04-18
SI2007756T1 (sl) 2015-11-30
JP2015120762A (ja) 2015-07-02
BRPI0710965B1 (pt) 2020-08-18
PT2674428T (pt) 2016-07-14
PT3091011T (pt) 2018-03-07
PL3327016T3 (pl) 2021-10-04
CA2648719C (en) 2015-02-24
US20220411410A1 (en) 2022-12-29
RU2451018C2 (ru) 2012-05-20
EP3091011B1 (en) 2017-12-27
EP3091011A1 (en) 2016-11-09
PL2007756T3 (pl) 2016-01-29
CY1116979T1 (el) 2017-04-05
EP2674428A1 (en) 2013-12-18
CY1120045T1 (el) 2018-12-12
JP2014031384A (ja) 2014-02-20
CN101460489A (zh) 2009-06-17
SI3091011T1 (en) 2018-06-29
BRPI0710965A2 (pt) 2012-01-31
LT3091011T (lt) 2018-04-10
JP5827297B2 (ja) 2015-12-02
SI2674428T1 (sl) 2016-07-29
US20070244159A1 (en) 2007-10-18
CA2869945A1 (en) 2007-10-18
EP2007756B1 (en) 2015-08-26
AU2007235260B2 (en) 2013-05-30
HUE026145T2 (en) 2016-05-30
NZ571803A (en) 2011-12-22
CA2869945C (en) 2018-01-23
JP2009533351A (ja) 2009-09-17
EP2007756A2 (en) 2008-12-31
EP3327016B1 (en) 2021-06-16
CA2648719A1 (en) 2007-10-18
US20240092766A1 (en) 2024-03-21
AU2007235260A1 (en) 2007-10-18
EP3327016A1 (en) 2018-05-30
NZ596889A (en) 2013-06-28
HUE027630T2 (en) 2016-10-28
US20100331344A1 (en) 2010-12-30
US9758510B2 (en) 2017-09-12
ES2882684T3 (es) 2021-12-02
US20200115366A1 (en) 2020-04-16
IL194576A0 (en) 2009-08-03
RU2008144124A (ru) 2010-05-20
US20140057906A1 (en) 2014-02-27
SI3327016T1 (sl) 2021-09-30
EP3882245A1 (en) 2021-09-22
IL194576A (en) 2016-12-29
PL3091011T3 (pl) 2018-06-29
ZA200809290B (en) 2009-10-28
US11639347B2 (en) 2023-05-02
NZ611485A (en) 2014-09-26
US8598181B2 (en) 2013-12-03
HUE036165T2 (hu) 2018-06-28
PL2674428T3 (pl) 2017-01-31
ES2554353T3 (es) 2015-12-18
MX2008012945A (es) 2009-01-15
WO2007117715A2 (en) 2007-10-18
PT2007756E (pt) 2015-11-02
DK3091011T3 (en) 2018-02-26
EP2674428B1 (en) 2016-04-06
CY1117731T1 (el) 2017-05-17
WO2007117715A3 (en) 2008-01-10
US7776905B2 (en) 2010-08-17

Similar Documents

Publication Publication Date Title
IN2014KN02423A (US20080318984A1-20081225-C00010.png)
MX357497B (es) Moduladores de transportadores de casete de union a atp.
HK1138586A1 (en) Modulators of cftr cftr
WO2010054138A3 (en) Modulators of atp-binding cassette transporters
HK1140475A1 (en) Azaindole derivatives as cftr modulators
WO2009038913A3 (en) Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
HK1148006A1 (en) Isoquinoline modulators of atp-binding cassette transporters atp
WO2006099256A3 (en) Modulators of atp-binding cassette transporters
NZ583878A (en) Modulators of ABC transporter and cystic fibrosis transmembrane conductance regulator (CFTR)
AU2010327993A8 (en) 4-oxo-1H-quinoline-3-carboxamides as modulators of ATP-Binding cassette transporters
WO2007044560A3 (en) Modulators of atp-binding cassette transporters
MX357328B (es) Moduladores de trasportadores de casete enlazante de atp.
MX365890B (es) Moduladores de transportadores con casete de uniĆ³n con atp.
WO2006127588A3 (en) Modulators of atp-binding cassette transporters
WO2009108657A3 (en) Heteroaryl derivatives as cftr modulators
NO20082674L (no) Heterocykliske modulatorer for ATP-bindende kassett-transportere
MX2008002019A (es) Moduladores del regulador de conductancia transmembrana de fibrosis quistica.
DE602004022819D1 (de) Von atp-bindende kassette transportern
WO2005026137A3 (en) Modulators of atp-binding cassette transporters
HK1092353A1 (en) Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters
NZ586271A (en) Fused pyrimidinone derivatives as modulators of cystic fibrosis transmembrane conductance regulator
EP2502911A3 (en) Modulators of ATP-binding cassette transporters